| | INFORMATION |
|-----|-------------------|
| DIS | SCLOSURE CITATION |

(Use several sheets if necessary)

| Atty. Docket No. | |
|------------------|--|
| 11020-55 | |

Serial No. 09/763,666

Applicant

Stephen R. Ash

Filing Date

Group

February 23, 2001

| | PADEMARK | U.S. | PATENT D | <u>OCUMEN</u> | ITS | | |
|----------------------|--|------------|-------------|---------------|----------|--------------|----------------------------|
| *Examiner Initial | DOCUMENT NUMBER | DATE | NA | ME | CLASS | SUBCLASS | Filing Date If appropriate |
| M | 4,364,929 | 12/21/1982 | Sasmor et | al. | 424 | 80 | |
| N | 4,677,143 | 06/30/1987 | Laurin et a | 1. | 523 | 122 | |
| 20 | 5,032,615 | 07/16/1991 | Ward et al. | , | 514 | 574 | |
| n | 5,665,061 | 09/09/1997 | Antwiler | | 604 | 4 | |
| n | 5,709,993 | 01/20/1998 | Buturovic- | Ponikvar | 435 | 2 | |
| N | 5,843,016 | 12/01/1998 | Lugnani et | al. | 604 | 21 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | 1.0 | 1 |
| | | FORE | IGN PATENT | DOCUME | ENTS | 78 | 2 |
| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | Trans Yes | Tation 70 |
| | | | | | | | 2 <u>H</u> |
| | | | | | | | VED 2001 |
| | ······································ | | | | | - 2 | <u>;</u> |
| | | | | | <u>.</u> | 3700 | 5 |
| | | | | | | | |
| Examiner 0 | | 1 | Date Con | sidered | -/-/ | | |
| | | 4 | = 2.5 50.1 | | 5/28/0 | ζ | |

*Examiner: initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Atty. Docket No. **11020-55**

Serial No. **09/763,666**

Applicant

Stephen R. Ash

Filing Date

Group

February 23, 2001

OTHER BURNENTS (Including Author, Title, Date, Pertinent Pages, Etc.) *Examiner Initial Olinger GN, Hottenrott C, Mulder DG, Maloney JV, Miller J, Patterson RW, Sullivan SF, Buckberg GD. Acute clinical hypocalcemic myocardial depression during rapid blood transfusion and postoperative hemodialysis. Journal of Thoracic and Cardiovascular Surgery 72: 503-511, October 1976. Dzik WH, Kirkley SP. Citrate toxicity during massive blood transfusion. Transfusion Medicine Reviews 2:76-94, June 1988. Kelleher SP, Schulman G. Severe metabolic alkalosis complicating regional citrate hemodialysis. Am J Kidney Dis 9: 235-236, March 1987. Lohr JW, Slusher S, Diederich D. Safety of regional citrate hemodialysis in acute renal failure. Am J Kidney Dis 8:104-107, February 1989. Leray-Moragues H, Bose LY, Canaud B. Gentamicin/sodium citrate mixture: a promising antibiotic lock for preventing catheter related infections. Lapeyronie Univerity Hospital, Montpellier, France. Von Brecht JH, Flanigan MJ, Freeman RM, Lim VS. Regional anticoagulation: hemodialysis with hypertonic trisodium citrate. Am J Kidney Dis 8:196-201, September 1986. Purchase L, Gault MH. Hemodialysis with a Permcath kept open with streptokinase and later citrate in a heparin-sensitive patient. Nephron 48:119-120, 1991. Flanigan MJ, Pillsbury L, Sadewasser G, Lim VS. Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A. Am J Kidney D 27:519-524, April 1996. Sodemann K, Lubrich-Birkner I, Berger O, Baumert J, Feldmer B, Von Hodenberg En Gentamicin/sodium-citrate mixture as antibiotic-lock technique for salvage and prevention catheter-related infections – A four year trial. J Am Soc Nephrol 8:173A, 1997. Examiner Date Considered

*Examiner: initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





*#137877 INFORMATION DISCLOSURE Atty. Docket No. Serial No. **CITATION** 11020-55 09/763,666 Page 3 of 301PE **Applicant** (Use several sheets if necessary Stephen R. Ash Filing Date Group AUG 1 7 2001 February 23, 2001 TS (Including Author, Title, Date, Pertinent Pages, Etc.) *Examiner **Initial** Buturovic J, Ponikvar R, Kandus A, Boh M, Klinkmann J, Ivanovich P. Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Artif Organs 22:945-946, 1998. Branson PK, McCoy RA, Phillips BA, Clifton GD. Efficacy of 1.4 percent sodium citrate in maintaining arterial catheter patency in patients in a medical ICU. Chest 103:882-885, March 1993.

*Examiner: initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Examiner ()

1020-96:GBC:192558 hder the Paperwork Reduction

PTO/SB/08A (12/01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE po persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Ubstitute for form 1449A/PTO **Application Number** 09/763,666 INFORMATION DISCLOSURE Filing Date February 23, 2001 STATEMENT BY APPLICANT First Named Inventor Stephen R. Ash Group Art Unit (use as many sheets as necessary) **Examiner Name** Sheet of Attornev Docket Number 11020-55

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|--------------|--------------|------------|--|---|--|--|
| Examiner Initials* | Cite No.1 | | | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | | | |
| P | | 6,166,007 | 12/26/2000 | Sodemann | | | |
| R | | 6,423,050 B1 | 07/23/2002 | Twardowski | | | |
| 10 | | 6,423,706 B2 | 07/23/2002 | Sodemann | | | |
| 1 | | 6,451,003 B1 | 09/17/2002 | Prosl et al. | | | |
| | | | | TECH. | RECEIVED DEC 0 9 2002 NOLOGY CENTER R3700 | | |

| Examiner Cite initials* No. | Cite | Foreign Patent Document | Publication Date | Name of Patentee or Application of Cited | Pages, Columns, Lines, Where Relevant Passages or Relevant | T ⁴ |
|-----------------------------|------|---|------------------|---|---|----------------|
| | No.¹ | Country Code ² -Number ⁴ -Kind Code ⁵ (if known) | MM-DD-YYYY | Document | Figures Appear | Ľ |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | Г |
| | | | | - | | |
| | | | | | | |
| | | | | | | |
| | | | | | 74 | |

| | | | · · · · · · · · · · · · · · · · · · · |
|-----------------------|--------|--------------------|---------------------------------------|
| Examiner Signature | Salvar | Date Considered | 5/28/03 |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.s. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the emperor must precede the serial number of the patent document. ⁵ Kind of document by the apOpropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.